Januriptin 50 mg (Sitagliptin Phosphate)
Sitagliptin Phosphate 62.04mg
Tablet · Prescription medication
Samchundang Pharmaceutical Co., Ltd.
MFDS item code 201503188 · Approved 2015.05.27
This product's status changed to Expired on 2025.05.27. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used to assist dietary and exercise therapy to improve blood sugar control in patients with type 2 diabetes. It can be administered as monotherapy and may be used in combination with metformin if achieving sufficient blood sugar control with monotherapy is difficult for patients who have never received diabetes medication treatment before. Additionally, this medication can be administered in conjunction with sulfonylureas, metformin, thiazolidinediones, or insulin when blood sugar control is inadequate with monotherapy. It can also enhance treatment effectiveness by adding this medication when blood sugar control is difficult with multiple-drug combination therapy. This medication effectively improves blood sugar control when used in various combination therapies.
Administer 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dosage adjustment according to renal function is required, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dosage adjustment is necessary in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is necessary in patients with moderate renal impairment (eGFR ≥ 45mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (eGFR ≥ 30mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (eGFR ≥ 15mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (eGFR < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.
This medication may cause severe allergic reactions, so if symptoms such as skin rash or difficulty breathing occur, discontinue use immediately and consult a physician. Acute pancreatitis, a serious pancreatic disease, may occur, so if symptoms such as abdominal pain or vomiting appear while taking this medication, immediate medical attention should be sought. It should not be used by patients with type 1 diabetes or those who have hypersensitivity reactions to this medication. Patients with impaired kidney function must adjust the dosage of this medication and take it according to the doctor’s instructions. Cold symptoms, headaches, or digestive disorders may occur while taking this medication; if symptoms are severe, consult a physician. The risk of hypoglycemia may increase when taken with other hypoglycemic agents, especially insulin or sulfonylureas, so regular blood sugar checks and dose adjustments may be necessary. If symptoms such as severe joint pain or blistering of the skin occur, discontinue use immediately and seek medical attention from a specialist. Pregnant or breastfeeding women are advised not to use this medication, and safety in children under 18 years has not been established. In older adults, renal function may decline, so regular kidney function tests before and after use are recommended, and dosage adjustments may be necessary. In case of overdose, seek immediate medical care for appropriate treatment, as this medication can be partially removed by hemodialysis. Due to potential interactions with other medications, be sure to inform healthcare providers of any medications currently being taken.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly sealed container to prevent air exposure, ideally at a temperature between 1 degree and 30 degrees Celsius. Proper storage will maintain the drug's efficacy and prevent degradation.
Light beige, biconvex, round film-coated tablet
30 tablets/box [(10 tablets/PTP) × 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate 62.04mg
Tablet · Prescription medication
Samchundang Pharmaceutical Co., Ltd.

Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Jongkeundang Co., Ltd.

Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Jongkundang Co., Ltd.

Sitagliptin Phosphate Hydrate 32.13mg
Tablet · Prescription medication
Jong Kundang Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Vivozon Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 32.125mg
Tablet · Prescription medication
Sinpoong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.